PAMELA DALE: Open Payments
NPI 1205172970 · CAMPTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$423 in 23 payments from 9 companies in 2025. Trend: 2023 $350 · 2024 $469 · 2025 $423
Food & beverage: $423
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 7 | $131 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $100 |
| AstraZeneca Pharmaceuticals LP | 4 | $65 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Amgen Inc. | 1 | $24 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Novo Nordisk Inc | 1 | $16 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $16 |
Products named: TRELEGY ELLIPTA, CAPLYTA, GEMTESA, AIRSUPRA, FARXIGA, OTEZLA, JOURNAVX, MOUNJARO.
Industry payments across KY — which companies pay providers there.
